SUPPLEMENTARY MATERIALS: Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial
收藏DataCite Commons2025-05-01 更新2025-04-16 收录
下载链接：
https://data.mendeley.com/datasets/vpb6m7gmhn
下载链接
链接失效反馈官方服务：
资源简介：
Supplementary materials for the publication of Armstrong A. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial. J Am Acad Dermatol 2022.
提供机构：
Mendeley
创建时间：
2022-10-19
